KRAS and BRAF mutation screening in metastatic colorectal cancer costly in relation to benefits
Wednesday, November 28, 2012 - 22:00
in Health & Medicine
Researchers report that screening for KRAS and BRAF mutations can reduce the cost of anti-EGFR treatment for metastatic colorectal cancer but with a very small reduction in overall survival according to a new study.